Brief: Abionyx Pharma Reports Positive Results From Phase 2A Trial Of Cer-001 For Septic Patients At High Risk Of AKI

Abionyx Pharma SA

16/01/2023 11:40

Jan 16 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A
PILOT
CLINICAL TRIAL EVALUATING CER-001 IN THE TREATMENT OF SEPTIC
PATIENTS AT HIGH RISK OF DEVELOPING ACUTE KIDNEY INJURY
    * EFFICACY RESULTS CONSISTENT WITH THOSE OBSERVED IN
COVID-19
    * TRIAL REINFORCES WELL-ESTABLISHED SAFETY PROFILE OF
CER-001
    * TRENDS TOWARDS FEWER ICU DAYS FOR PATIENTS TREATED, LOWER
REQUIREMENT FOR ORGAN SUPPORT AND IMPROVED 30-DAY SURVIVAL WERE
ALSO SEEN
    * SIGNIFICANT PROTECTIVE EFFECT OF CER-001 ON ENDOTHELIAL
FUNCTIONALITY
    * CLINICAL STUDY WAS PARTNERED WITH UNIVERSITY OF BARI

Source text for Eikon:  ID:nBw7YJWPza 
Further company coverage:  ABNX.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))